Research programme: MNK1/MNK2 inhibitors - Selvita

Drug Profile

Research programme: MNK1/MNK2 inhibitors - Selvita

Alternative Names: MKNK1/MKNK2 protein inhibitors; MNK1/2 kinase inhibitors - Selvita; SEL201

Latest Information Update: 10 Nov 2015

Price : $50

At a glance

  • Originator Selvita
  • Class Small molecules
  • Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Nov 2015 Preclinical trials in Cancer in Poland (unspecified route)
  • 11 Nov 2014 Early research in Cancer in Poland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top